Acceptance of the respiratory syncytial virus infant monoclonal antibody nirsevimab among post-partum women in Italy Authors: Silvia Angelillo, Grazia Miraglia del Giudice, Giorgia Della Polla, Italo Francesco Angelillo, The Collaborative Working Group Published: 2026 ABSTRACT ABSTRACTThe purposes of the cross-sectional survey were to investigate among a sample of post-partum women in Italy the attitudes and the behaviors about the respiratory syncytial virus (RSV) infant monoclonal antibody and to explore any associations with different characteristics.The survey was conducted between March and April 2025 in teaching and public hospitals randomly selected in Southern Italy. The data were collected using a structured questionnaire through a face-to-face interview for those women in the maternity wards and by telephone for those who were at home.A total of 476 women completed the interview for a response rate of 96.6%. Half (50.8%) reported that the monoclonal antibody was very useful for the protection of the newborn, and this was more likely among mothers who trusted the information they received about vaccinations and those who had not received information from Internet or social media. A total of 86.5% had immunized their newborn against RSV. Women who had received at least one vaccination when pregnant, those who believed that the monoclonal antibody was very useful, those who did not acquire information from Internet or social media, and those who trusted the vaccination information acquired were more likely to have immunized their child.Education and communication strategies must be embedded in pre-natal and maternal health programs, and healthcare workers must be encouraged to actively inform and counsel every new cohort of pregnant women about the role of the RSV immunization to protect their children.KEYWORDS: Infection, newborn, post-partum, respiratory syncytial virus, vaccines/vaccine strains, women Introduction Respiratory syncytial virus (RSV) is the primary cause of hospitalization for bronchiolitis and for other lower respiratory tract infections, mainly among newborns, infants, and children aged younger than 5 y. It is estimated that RSV is responsible for more than 33 million cases of lower respiratory tract infection in children younger than 5 y of age, with more than 3.6 million hospitalizations and over 100,000 deaths each year worldwide.1,2 In October 2022, the European Medical Agency approved Nirsevimab, a monoclonal antibody for the prevention of RSV-associated diseases administered via intramuscular injection to a child before or during the RSV season with a single dose of 50 mg (in infants weighing less than 5 kg) or 100 mg (in those weighing 5 kg or more) that has shown long-lasting protection for 5 months or longer after administration.3 In November 2024, Italy launched, up to April 14, 2025, a free national immunization campaign targeting newborns either in the birth hospital before discharge or in primary healthcare setting for infants born since August 1, 2024.4 Women’s knowledge and acceptance of RSV infant monoclonal antibody during pregnancy and post-partum period may be of particular importance to reduce the burden of bronchiolitis and for other lower respiratory tract infections among their children. However, a detailed understanding of whether pregnant women or parents of young children have positive attitudes and appropriate behaviors on this monoclonal antibody is currently limited5–10 and to the best knowledge of the authors, no surveys have been conducted in Italy. Thus, in-depth research is needed to investigate and understand this topic as a crucial step toward effective public health strategies and tailoring interventions to empower this target population to make informed choices. Therefore, the clear purposes of the present cross-sectional survey were to investigate among a sample of post-partum women in Italy the attitudes and the behaviors about the RSV infant monoclonal antibody and to explore any associations with different characteristics. Materials and methods Study design and participants The survey was conducted over a two-month period between March and April 2025 in two teaching and two public hospitals randomly selected in the Campania region, Southern part of Italy. During this period, a total of 1540 women delivered in the selected hospitals. From this population, a random sample of 493 women was recruited, including 91 women who were in maternity wards during their post-partum stay up to April 14, 2025, and 402 women who had given birth at these four hospitals since August 1, 2024, and had already returned home. Newborns could receive the RSV antibody either prior or after hospital discharge. The minimum sample size was determined assuming the prevalence of the RSV infant monoclonal antibody uptake at 50%, with a 95% confidence interval, and a 5% type one error. Assuming a non-response rate of 10%, a minimum sample size of 427 women was recruited. Data collection A formal letter was sent to each hospital health director explaining the purpose of the survey, asking for permission to interview the women in the maternity wards, and requesting the database with detailed information and phone numbers of any women who had given birth since August 1, 2024, and who returned home. Upon getting the permission, three trained researchers collected the data using a structured questionnaire through a face-to-face interview for those women in the maternity wards and a telephone interview for the women who were at home. The data collection process started with a brief introduction on the survey’s purpose and methodology, that no identifying information or personal identifiers will be collected during the interview to maintain confidentiality and privacy throughout the survey procedure, that their participation was entirely voluntary, and that the information would be used for scientific purposes. Verbal informed consent was obtained from all participants before the interview and documented in the study records, including date and participant identifier. Participants were also informed that they had a full right to withdraw at any time before completing the questionnaire without explanation. The participants were not offered any incentives or compensation for answering the questionnaire. The survey obtained ethical approval from the Ethics Committee of the Teaching Hospital of the University of Campania “Luigi Vanvitelli” (protocol code: 0016978/i). Questionnaire The questionnaire was designed by the research team based on a similar previous survey conducted by some of us.11 A pilot study among 20 women was conducted to verify the clarity and wording of the questionnaire. As no corrections and modifications were made, the pilot study results were included in the final analysis. Internal consistency reliability was evaluated using Cronbach’s alpha coefficient, which indicated good internal consistency for the questionnaire (α = 0.8494). The questionnaire contained four sections, and the average time for each interview was about 15 min. The first section asked socio-demographic and health-related questions about themselves and the newborn, such as age, educational level, relationship status, employment status, number of children, self-reported history of chronic disease, and lastly the newborn’s gender and Neonatal Intensive Care Unit (NICU) admission history. The second section contained five questions to address respondent’s beliefs about the monoclonal antibody, using a 10-point Likert-type scale scored from “1” for the less desirable attitude and “10” for the most desirable, including the perceived safety and effectiveness of the monoclonal antibody, how dangerous could be for the newborn to acquire the RSV infection, the concern and the perceived risk that the newborn could be infected by RSV. Hesitancy regarding childhood vaccinations was measured with the five items of the Parent Attitudes about Childhood Vaccines (PACV) Survey Tool using a 5-point Likert scale with responses ranging from strongly disagree, disagree, uncertain, agree, to strongly agree.12,13 A score of 0–2 has been assigned to each item, with non-hesitant responses receiving a score of 0, responses of “not sure” a score of 1, and hesitant responses a score of 2. The total score ranged from 0 (non-hesitant) to 10 (most hesitant) per person and the hesitancy was categorized as low (0–4), moderate (5–6), and high (7–10). The third section contained questions on the behavior regarding the uptake of the monoclonal antibody. Respondents answered with the options of “yes” and “no” and a list of potential main reason/s behind their behavior was provided with the instructions to select as many they want. Then, participants who responded that their child had not received the monoclonal antibody were asked their willingness or unwillingness to administer the antibody. The response options were “yes,” “no,” and “do not know,” and, finally, they were asked the reason/s behind their intention with a multiple-choice option. Participants were also asked whether they had been offered any recommended vaccinations during pregnancy and if they had received them, with “yes” and “no” as response options. In the last section, participants were asked to indicate the sources of RSV infant monoclonal antibody information using close-ended questions and whether they would like to obtain further information about RSV infant monoclonal antibody measured using a 10-point Likert-type scale ranging from 1 “not at all” to 10 “at all.” Statistical analysis The statistical analysis consisted of three phases. First, the key characteristics of the participants were summarized using frequencies and percentages for categorical variables and mean, range, and standard deviation for continuous variables. Second, a bivariate analysis was performed to examine associations between each categorical or continuous variable and the outcomes of interest using chi-square test or Student’s t-test, respectively. Third, multivariate linear and logistic regression models were constructed to determine which factors were independently associated with the outcomes of interest by including all variables with a p-value equal to or less than .25 in the bivariate analysis. A stepwise procedure aimed at selecting the variables was employed, alternating between deletion and addition of the variables based on p = .2 and p = .4, respectively. The outcomes of interest were the following: perceived utility of the RSV infant monoclonal antibody (continuous) (Model 1); having immunized the newborn with the RSV infant monoclonal antibody (no = 0; yes = 1) (Model 2). The following independent variables have been tested for all outcomes: age, in years (continuous), married/cohabited with a partner (no = 0; yes = 1), having another child (no = 0; yes = 1), employed (no = 0; yes = 1), having the newborn admitted in NICU (no = 0; yes = 1), having received information about RSV from Internet or social media (no = 0; yes = 1), need of additional information about RSV (continuous), having received at least one vaccination during pregnancy (no = 0; yes = 1), having received information about the recommended vaccinations for the newborn (no = 0; yes = 1), and having trust in the information received about vaccinations (strongly disagree/disagree/not sure = 0; strongly agree/agree = 1). The independent variables concern that the newborn could be infected by RSV (continuous), believing that the newborn is at risk of being infected by RSV (continuous), believing that the RSV infection is dangerous for the newborn (continuous), perceived utility of the RSV infant monoclonal antibody (continuous), and being concerned about the side effects of the RSV infant monoclonal antibody (continuous) have been tested in Model 2. The results of multivariate regression analysis are presented for the logistic model as odds ratios (OR) with corresponding 95% confidence intervals (CI) and for the linear model as the β coefficient. Statistical significance was established at a two-tailed p-value equal to or less than .05. All statistical analyses were conducted using Stata version 18. Results In total, 476 of the randomly selected women provided consent and completed the interview for a response rate of 96.6%. Of these participants, 389 were recruited by telephone at home (response rate: 96.8%), while 87 women were interviewed in person during their post-partum hospital stay using a face-to-face questionnaire (response rate: 95.6%). Principal characteristics of the respondents are summarized in Table 1. The mean age was 33.9 y (range 17–54), 91.6% were married or cohabited with a partner, 11.7% were employed in a medical-related occupation, more than half reported completing either a baccalaureate graduate degree or higher, more than half were primiparous, 6.7% had at least one chronic disease, and for more than half the newborn was female. Table 1.Socio-demographic and anamnestic characteristics of the study population. N†%Age, years33.9 ± 5.4 (17–54)*Marital status Married/cohabited with a partner43491.6 Unmarried/separated/divorced408.4Educational level High school degree or less23048.3 Baccalaureate graduate degree or higher24651.7Employment status Unemployed16434.5 Employed25653.8 HCWs5611.7Having at least one chronic disease No44493.3 Yes326.7Number of children 127557.8 214831.1 >25311.1Newborn gender Male22647.9 Female24652.1Newborn admitted in NICU No40785.5 Yes6914.5*Mean±standard deviation (range).†Number for each item may not add up to total number of study population due to missing value. RSV: respiratory syncytial virus. HCWs: Healthcare Workers. NICU: Neonatal Intensive Care Unit. Socio-demographic and anamnestic characteristics of the study population. *Mean±standard deviation (range). †Number for each item may not add up to total number of study population due to missing value. RSV: respiratory syncytial virus. HCWs: Healthcare Workers. NICU: Neonatal Intensive Care Unit. Participants’ responses to questions concerning their beliefs about the RSV monoclonal antibody, measured on a Likert-type scale ranging from 1 to 10, showed that the mean value of their concern that the newborn could acquire the RSV infection was 7.4, with almost one-third had responded 10, and the mean value of the belief that the newborn was at risk of acquiring this infection was 5.8 with only 12.2% considered them at high risk. A higher score with a value of 8.1 has been observed for the statement that acquiring this infection can be dangerous for their newborn with 40.7% indicated 10. In terms of perceived utility, half (50.8%) reported that the RSV monoclonal antibody was very useful for the protection of the newborn, with a mean value of 8.6. Regarding safety, more than one-fifth (22.1%) were very concerned about the side effects, with a mean value of 6.1. Table 2 showed the multivariate linear and logistic regression analysis to identify the factors associated with the different outcomes of interest. In the multivariate linear regression model, two variables remained significantly associated with the attitude toward the RSV infant monoclonal antibody. Mothers who trust the information they received about vaccinations and those who had not received information about RSV from Internet or social media were more likely to believe that the infant monoclonal antibody was very useful for the protection of the newborn (Model 1). Table 2.Results of the linear and logistic regression analysis showing the factors associated with the outcomes of interest.Model 1. Perceived utility of the RSV infant monoclonal antibodyF (5,461) = 8.10, R2 = 8.07%, adjusted R2 = 7.08%, p < .0001VariablesCoeffSEtpHaving trust in the information received about vaccinations0.780.203.75<.0001Not having received information about RSV from Internet or social media−0.530.19−2.67.008Need of additional information about RSV0.060.03 1.86.063Employed0.330.181.79.074 Older0.020.011.38.167 Model 2. Having immunized the newborn with the RSV infant monoclonal antibodyLog likelihood = −154.87896, χ2 = 64.61 (df = 7), p < .0001 ORSE95% CIp Higher perceived utility of the RSV monoclonal antibody1.380.091.21–1.57<.0001 Having received at least one vaccination during pregnancy2.390.821.21–4.69.011 Not having received information about RSV from Internet or social media0.520.150.28–0.94.031 Having trust in the information received about vaccinations1.910.611.02–3.59.043 Not being concerned about the side effects of the RSV monoclonal antibody0.920.050.83–1.02.145 Having received information about the recommended vaccinations for the newborn1.670.720.71–3.91.233 Having the newborn admitted in NICU1.640.790.63–4.23.302 RSV: respiratory syncytial virus; NICU: Neonatal Intensive Care Unit. Results of the linear and logistic regression analysis showing the factors associated with the outcomes of interest. RSV: respiratory syncytial virus; NICU: Neonatal Intensive Care Unit. A total of 86.5% of the surveyed women responded that their newborn had received the RSV monoclonal antibody either prior to hospital discharge (53%) or following discharge (47%). The results of the multivariate logistic regression analysis showed that four variables were independently significantly associated with having immunized their child. Women who had received at least one vaccination when pregnant had over twofold higher odds of having immunized their child as compared with those who had not been vaccinated (95% CI = 1.21–4.69). Respondents who believed that the RSV infant monoclonal antibody was very useful for the protection of the newborn were 38% more likely to have immunized their child than those who perceived a lower utility (95% CI = 1.21–1.57). Those who trusted the vaccination information acquired had nearly twofold higher odds of having immunized their child compared with women who distrusted (95% CI = 1.02–3.59). Further, women who have received information about the RSV monoclonal antibody from Internet or social media were 48% less likely to have immunized their children than those who had not used these sources (95% CI = 0.28–0.94) (Model 2 in Table 2). The major reason that has been indicated by the women for having immunized their child was the protection of the child from the infection (77.7%), but they also stated other reasons such as that the Pediatrician has recommended it (22.7%) and concern that RSV can cause a serious illness (21.3%). Conversely, among women who had decided not to immunize their newborn, the most prevalent reason was a lack of information (25%), followed by concern of side effects (18.7%), and a lack of recommendation by the healthcare personnel in the hospital setting (15.6%). Among the survey respondents who had not immunized their children, 51.6% expressed a positive intention to immunize the newborn and the main reasons were for their protection (52.9%) or they would do so if recommended by a Pediatrician (47.1%), Gynecologist (23.5%), and healthcare personnel in the hospital setting (20.6%). Almost half of the participants (45.2%) revealed that safety concern was the main barrier to their unwillingness or uncertainty to immunize, followed by a lack of information (25.8%) and because it has been approved too recently (25.8%). The overall mean PACV-5 score was 2.4 with only 8.9% of the respondents classified as high-vaccine hesitant for their child having scored ≥7; 11.8% as moderate-hesitant scoring between 5 and 6, and 79.3% as low-hesitant scoring ≤ 4. Responses to the individual items of the PACV-5 are shown in Table 3. Almost one-third (32.8%) and half (46.9%) of mothers thought or were uncertain that the children had more vaccines than were necessary and wanted children to receive fewer vaccines at the same time, respectively. Less than one-fourth (23%) strongly agreed or were uncertain that was better to acquire immunity through the disease than through vaccination. More than three-quarters (78.3%) trusted the information they received about vaccinations. Overall, 18.4% evaluated themselves as vaccine hesitant about childhood vaccinations. Table 3.Descriptive characteristics of respondents’ PACV-5 about vaccinations.ItemParticipants’ responseN%Children get more vaccines than are necessary for them Strongly agree112.3 Agree7415.7 Not sure7014.8 Disagree20042.3 Strongly disagree11824.9It is better for children to get fewer vaccines at the same time Strongly agree112.3 Agree9920.9 Not sure11223.7 Disagree16033.8 Strongly disagree9119.3It is better for children to acquire immunity through the disease than through vaccination Strongly agree20.4 Agree357.4 Not sure7215.2 Disagree22948.4 Strongly disagree13528.6I trust the information I received about vaccinations Strongly agree10221.6 Agree26856.7 Not sure7916.7 Disagree224.6 Strongly disagree20.4Overall, how hesitant about the vaccinations for your child would you consider yourself to be? Very hesitant112.3 Somewhat hesitant7616.1 Not sure11123.5 Not too hesitant10021.1 Not hesitant at all17537Number for each item may not add up to the total number of the study population due to missing values.PACV: Parent Attitudes about Childhood Vaccines. Descriptive characteristics of respondents’ PACV-5 about vaccinations. Number for each item may not add up to the total number of the study population due to missing values. PACV: Parent Attitudes about Childhood Vaccines. Overall, 83% of mothers have acquired information about RSV and 53.4% of them mentioned that used more than one source. Pediatricians were their main source (39.9%), followed by family members and friends (33.9%), Internet (31.9%), Gynecologists (15.3%), and social media (11.1%). The mean value of participants’ need of information about RSV measured on a 10-point Likert-type scale was 7.6, and one-third (33.2%) indicated the score of “10” meaning a higher need. Discussion The findings of this survey provided a first relevant and valuable understanding into post-partum women’s attitudes and behaviors regarding the RSV infection and infant monoclonal antibody, as well as their potential influencing determinants in Italy. The findings highlight several key points. First, even though the RSV infant monoclonal antibody is a new preventive measure, a pivotal result was that a substantial majority of surveyed post-partum women (86.5%) had immunized their newborn. This is like a recent survey among post-partum women in Luxembourg which reported a value of 84% in maternity wards ranging from 66% to 94%.14 The value was slightly lower than the coverage of 91.6% among newborns in hospital’s maternity department in France9 and 91.5% in those born during the campaign and 85.1% in those born before the beginning of it in Spain.6 It should be underlined that the coverage was higher compared to those reported in four surveys from the United States where the monoclonal antibody was administered to 70.1% eligible infants prior to hospital discharge,15 47.3% in pediatric primary care,16 35%17 and 19% during RSV season.18 Among the participants who had not immunized their newborn, encouragingly, more than half exhibited a positive attitude by expressing their intention to administer the monoclonal antibody. Similar previous surveys, although conducted among pregnant women, found higher willingness with values of 92% in Canada5, 87% in Spain,6 78% in the UK among participants with a child under the age of 2 y and/or pregnant,7 in the Netherlands among expectant parents,8 and 68% in the United States among adults with children if they were to have a new baby.19 Variations in uptake and willingness may be partly explained to differences in mothers’ socio-demographic and cultural characteristics, surveys’ methodology, implementation of immunization campaigns and information, level of trust in health care systems, and public health policies. Second, the attitude-related findings toward the RSV infant monoclonal antibody showed that a large portion of respondents had a positive attitude. It was noted that over half of the respondents felt positive about its utility and more than one-fifth had safety concerns. Interestingly, this level of perceived utility is notably higher than that observed in a previous study conducted in the same geographic area, in which only one-fifth of pregnant women believed that a hypothetical RSV vaccine for newborns would be very useful.11 This result is encouraging and, although the outcome was different, may reflect the positive effects of recent immunization campaign on the improvement of public awareness about the prevention of the RSV infection in infants. Regarding the RSV infection, almost one-third of the mothers expressed great concern that the newborn could be infected, although only 12.2% and 40.7%, respectively, considered the newborn belonging to a high-risk group of acquiring the infection and perceived that acquiring it can be dangerous. Similar results have been observed in previous investigations in different geographic areas, such as in the United States where only one-third of pregnant women agreed that their child was likely to contract RSV, 41% believed that the symptoms would be mild if their child was infected, and only 22% thought that medical care would be necessary,19 In China, 26.1% of parents were unaware that infants and young children are at a high risk of RSV infection and 41.2% believed that their child was likely to be susceptible,20 and in Spain the 49% expressed concern about the frequency of RSV infection in children.21 The gap in understanding severity, risk factors, and potential consequences of the RSV infection underlines the importance of improving mothers’ knowledge of the disease burden associated with the RSV infection and about the high preventive usefulness and safety of immunization with monoclonal antibody that is crucial to achieve adequate coverage. Additionally, considering that risk perception is likely to be related to the level of knowledge, communication and more information regarding the infection is needed. Third, the predominant reasons women chose to immunize their newborn were the protection from infection followed by a Pediatrician’s recommendation and concern that RSV can cause a serious illness. Although only one-fifth had received recommendations from Pediatricians, this is important since they are uniquely positioned to promote immunization and to influence the parents’ decision. A large body of previous literature has underlined the value that parents and other groups of individuals place in receiving recommendations from Pediatricians, and more generally from healthcare workers. Indeed, their recommendation has a positive impact on the decision of the individuals to vaccinate themselves or their child and to be less vaccine hesitant than those who did not receive the recommendation.22–25 Another interesting finding was that Pediatricians were identified as the most used source of information. Their crucial role in communicating to the public the importance of immunization and advocating for preventive measures is supported by the fact that one of the main reasons associated with the positive intention to immunize the child was using a Gynecologist, a Pediatrician or healthcare personnel as a source of monoclonal antibody-related recommendation for their children. Of importance is the negative influence of acquiring information from Internet and social media on the outcomes of interest that is evident in the multivariate linear and logistic regression analysis. Mothers who received information from these sources were more likely to believe that the monoclonal antibody was less useful for the protection of the newborn and less likely to have immunized their child compared to parents who got information from healthcare personnel, governmental sources, and family members or friends. Although this association may seem unexpected in light of the widespread availability of online health information, it is consistent with a large body of evidence from different countries showing that the use of Internet and social media does not always play a positive role, since it has been associated with individual’s skepticism regarding the efficacy and safety and vaccine hesitancy with a negative impact on the willingness or on the acceptance mainly for the proliferation of misinformation.26–28 This finding may be explained by the widespread presence of low-quality, misleading, or inaccurate health information on Internet and social media platforms. Such information can amplify vaccine-related fears and reinforce misinformation in immunization programs, especially when it is disseminated by non-authoritative sources. As a result, individuals who do not rely on Internet and social media are less exposed to misinformation, making them less susceptible to misleading health claims and, consequently, more likely to engage in appropriate vaccination-related behaviors. This survey also assessed the reasons behind participants’ not immunizing or unwilling to immunize their newborn. Understanding these reasons is key to implementing interventions necessary for the success of immunization programs. According to the data, one of the predominant reason for not being immunized was the lack of recommendation by healthcare workers, whereas for their unwillingness or uncertainty, safety concern was the main barrier. These observations emphasize that training of healthcare personnel is needed to improve their knowledge on immunization and communication skills to overcome the misconceptions and concerns about the RSV monoclonal antibody safety of their patients. Healthcare personnel have also an important role in advocacy, and therefore, it is imperative to disseminate comprehensive information about the RSV infection and the monoclonal antibody to prevent the infection and protect the newborn. This is also supported by the finding that one-third of the respondents indicated that they needed additional information. Fourth, it should be noted that the mean PACV-5 score was 2.4, with only 8.9% of the women classified as highly vaccine hesitant for their child. When comparing this prevalence to previous research in the existing literature, the value is lower than those that have been found regarding routine infant immunizations with values of 21.6% in the United Arab Emirates,29 21.2% in Sub-Saharan Africa,30 27% in Netherlands,31 and 52.4% in Japan,32 while a lower hesitancy rate of 2.6% was observed in China among parents of girls regarding HPV vaccination.33 This is surprising since the RSV infant monoclonal antibody is a new strategy and, therefore, may face greater skepticism due to limited familiarity. The observed level of hesitancy, even if lower than others, underscores the need of improving vaccine confidence among parents. Moreover, this survey revealed almost one-fourth of “not sure” responses when asked whether children should receive fewer vaccines at the same time and 14.8% believed that children get more vaccines than are necessary. This finding warrants careful interpretation. Such responses could indicate genuine parental uncertainty regarding vaccination or insufficient information. These “not sure” responses again underscore the importance of considering targeted public health education and communication strategies, specifically for addressing parents’ information regarding routine vaccines by adopting a participatory approach and explaining with accurate and clear information the rationale behind the recommended schedule. Fifth, the multivariate linear and logistic regression analysis further identified several predictors associated with the outcomes of interest. It is extremely important to understand these factors to develop effective strategies among sub-populations with characteristics who were more likely to have lower coverage or lower intentions to immunize their children. It was unsurprising that mothers who had received at least one of the recommended vaccinations during pregnancy had a significantly higher likelihood of having immunized their newborn compared to those unvaccinated. This may attribute to the fact that mothers vaccinated are more likely to adhere to preventive measures also for their children, including the administration of recommended immunizations. This is an expected result and was in line with what has been described in earlier surveys which demonstrates higher rates of vaccination among children of vaccinated parents34–37 and underscore the need for prenatal discussions and interaction between healthcare workers and pregnant women. Another significant independent predictor associated with the immunization uptake was the belief toward the RSV monoclonal antibody, since mothers with a higher perceived utility had greater odds of having immunized their newborn than those who belief that it was less useful. This evidence aligns with recent research indicating that individuals’ positive attitude or perceptions could potentially serve as facilitators to improve the uptake, since they generally are more likely to exhibit greater willingness or to participate in vaccination programs than those with negative attitude or perceptions.38,39 These findings highlight the need to strengthen parental understanding of the effectiveness of the RSV monoclonal antibody through educational interventions that communicate the benefits and effectiveness. Finally, trust in the vaccination information acquired was a significant positive predictor of attitudes and behaviors, and it is not surprising that this determinant was associated with the immunization of the newborn and with the mothers’ belief that the monoclonal antibody was very useful for the protection of the newborn. Caution is warranted when interpreting and drawing conclusions from the results of the present survey, considering the following potential methodological limitations. First, the cross-sectional nature of the data poses challenges, as for all surveys with this design in general, in establishing temporality and causal relationships between the characteristics studied and the outcomes observed. Second, the participants were recruited in a single geographic area, and they might not fully reflect the broader population of pregnant and post-partum women in Italy with the findings that may lack generalizability beyond the surveyed sample. Third, self-reported responses may be prone to social desirability bias. Therefore, responses, mainly concerning the administration of the monoclonal antibody, were not verified with medical records, impacting the accuracy of the information collected. Some participants may also have been tempted to answer in a manner that they perceived as more acceptable to the research team rather than accurate reflections of their views or behaviors. This possibility has been mitigated by clearly informing participants about the confidentiality and anonymity of survey data. Despite these limitations, the survey offers valuable insights for healthcare personnels’ practice and policy. In conclusion, the survey revealed that the RSV infant monoclonal antibody immunization uptake was remarkably high and also more than half of the women indicated an intention to immunize their child. The findings provide information to policymakers and since each RSV season introduces new cohorts of pregnant women, education and communication strategies about the RSV infection and infant monoclonal antibody must be embedded in pre-natal and in maternal health programs and healthcare workers must be encouraged to actively inform and counsel this target group about the role of the immunization to protect their children. Acknowledgments The authors sincerely express their gratitude to all women who participated in this survey. The members of the Collaborative Working Group provided the database with detailed information and phone numbers of the participants. Biography Italo Francesco Angelillo is a Full Professor of Hygiene at the Medical School of the University of Campania “Luigi Vanvitelli,” Italy. At the Harvard University (Boston, MA, USA), he was a Visiting Scholar at the School of Public Health in the Department of Health Policy and Management and at the School of Dental Medicine in the Department of Dental Care Administration, and he has also received an MPH at the School of Public Health. He is Director of the Department of Public Health and Laboratory Services and of the Unit of Hospital Hygiene in the Teaching University Hospital and Vice Rector of the University of Campania “Luigi Vanvitelli.” The research activity focused on the level of knowledge of infectious diseases and of the main preventive measures, the attitudes regarding the risk of acquiring infectious diseases, and the behavior toward preventive measures among several at-risk groups of population. Funding Statement The work was supported by the Italian Ministry of University and Research (MUR) under the Italian Piano Nazionale di Ripresa eResilienza (PNRR), Grant BEHAVE-MOD (ID: COC-1-2023-ISS-02 INF-Act). Contributor Information Collaborators: Carlo Capristo, Francesco Tarsitano, Ilias Urciuoli, and Emilia Anna Vozzella Disclosure statement No potential conflict of interest was reported by the author(s). Data availability statement The data presented in this survey are available upon request from the corresponding author. References Associated Data Data Availability Statement The data presented in this survey are available upon request from the corresponding author.